Clinicians and families often seek natural non-pharmacological approaches to ADHD in children and adolescents. This hope has spawned a growing body of preliminary research on many supplements and diets for ADHD. This research update on a study of the DASH diet offers our thinking about its possible usefulness for our patients.

What is important to patients as they choose a treatment setting? This retrospective analysis examines online ratings and reviews that patients in specific Pennsylvania drug treatment facilities completed from 2010-2018 to assist in identifying quality metrics.

Loneliness is a readily measurable phenomenon and it predicts worse outcomes in addiction treatment on the individual and population levels. What can we do in the clinic to combat loneliness and promote social cohesion?

Faith may be a protective factor against addiction, and some widely accepted treatments use faith to build recovery capacity. This article reviews the evidence for faith-based treatment and provides suggestions for incorporating faith in the clinic.

In this QA, we review the findings of placebo- controlled trials done over the past 10 years on depression in kids and the discuss the current recommendations for medication treatment of depression in children and adolescents.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.

In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.